1-3 of 3
Vadim V. Romanov, MD MPhil, FFPM
Close
Sort by
Journal Articles

Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study

Richard T. Maziarz, MD, Stephen J. Schuster, MD, Vadim V. Romanov, MD MPhil, FFPM, Elisha S. Rusch, PhD, James Signorovitch, PhD, Solveig G. Ericson, MD PhD, David G. Maloney, MD PhD, Frederick L. Locke, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4183.
https://doi.org/10.1182/blood-2018-99-118595
Published: 2018
Journal Articles

Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study

Stephen J. Schuster, MD, Richard T. Maziarz, MD, Solveig G. Ericson, MD PhD, Elisha S. Rusch, PhD, James Signorovitch, PhD, Vadim V. Romanov, MD MPhil, FFPM, Frederick L. Locke, MD, David G. Maloney, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4190.
https://doi.org/10.1182/blood-2018-99-113052
Published: 2018
Journal Articles

Safety and Efficacy of Tisagenlecleucel Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and No Evidence of Active Disease Following Bridging Chemotherapy in the JULIET Trial

Michael R. Bishop, MD, Richard Thomas T. Maziarz, MD, Edmund K. Waller, MD, Christopher del Corral, PharmD, Ranjan Tiwari, MSc, Özlem Anak, MD, Rakesh Awasthi, PhD, Vadim V. Romanov, MD MPhil, FFPM, Stephen J. Schuster, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2958.
https://doi.org/10.1182/blood-2018-99-115094
Published: 2018